Hospital
VHS Acquisition Subsidiary Number 1 INC
VHS Acquisition Subsidiary Number 1 INC was paid $24.35M by Medicaid between Jan 2018 and Dec 2024, across 199 billing codes. Its largest line is 99285, emergency room visit (most serious) — 24% of everything it billed.
33Billing provider infoVHS ACQUISITION SUBSIDIARY NUMBER 1 INC
PHOENIX, AZ 85032
PHOENIX, AZ 85032
33aNPI1326022732assigned 11/30/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$24.35M
24GClaims607,159
24DCodes billed199
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#24 of 78
Median peer was paid$12.21M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 105,344 | $3.70M | |
| 2019 | 90,667 | $3.57M | |
| 2020 | 82,292 | $3.12M | |
| 2021 | 90,733 | $3.44M | |
| 2022 | 89,469 | $3.80M | |
| 2023 | 86,978 | $3.77M | |
| 2024incomplete | 61,676 | $2.95M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 24% | 18,779 | 16,915 | $5.85M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 25,024 | 22,997 | $4.69M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 26,375 | 24,558 | $4.47M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 14% | 5,194 | 4,857 | $3.31M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 6.1% | 3,440 | 3,211 | $1.48M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 5,987 | 5,717 | $668K |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.5% | 2,266 | 2,111 | $602K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 6,598 | 6,045 | $535K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.7% | 745 | 734 | $422K |
| C1776 | Joint device (implantable) | 1.4% | 102 | 91 | $347K |
| G0378 | Hospital observation service, per hour | 1.1% | 6,938 | 3,275 | $257K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,581 | 812 | $231K |
187 more codes
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,055 | $223K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 375 | $182K |
| 93971 | <1% | 838 | $151K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,509 | $113K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,063 | $96K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,348 | $93K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 19,702 | $88K |
| 72131 | <1% | 330 | $82K | |
| 70498 | <1% | 110 | $53K | |
| 59025 | Fetal non-stress test | <1% | 318 | $47K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 226 | $43K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,699 | $32K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 333 | $31K |
| 80053 | Comprehensive metabolic panel | <1% | 30,636 | $24K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 461 | $24K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,170 | $23K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,285 | $22K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,689 | $22K |
| 70486 | <1% | 351 | $14K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,244 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,618 | $11K |
| 96376 | <1% | 4,479 | $10K | |
| 29581 | <1% | 91 | $8K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 225 | $8K |
| 93970 | <1% | 26 | $6K | |
| 73130 | <1% | 1,105 | $6K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,024 | $5K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,903 | $5K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,219 | $5K |
| 73630 | <1% | 1,159 | $4K | |
| 73562 | <1% | 1,026 | $4K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 309 | $4K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,309 | $4K |
| 73700 | <1% | 26 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,146 | $3K |
| 87400 | <1% | 5,792 | $3K | |
| 73030 | <1% | 1,098 | $3K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,462 | $2K |
| 73610 | <1% | 1,049 | $2K | |
| 80061 | Lipid panel | <1% | 1,022 | $2K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 37,836 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,791 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 14,135 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,818 | $1K |
| 12001 | <1% | 205 | $1K | |
| 81025 | <1% | 8,607 | $1K | |
| 97162 | <1% | 240 | $1K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,893 | $1K |
| 88342 | <1% | 52 | $906.53 | |
| 10060 | <1% | 51 | $895.18 | |
| 29125 | <1% | 186 | $874.84 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,196 | $752.40 |
| 83690 | <1% | 12,500 | $724.03 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 162 | $641.75 |
| 84484 | <1% | 11,215 | $577.28 | |
| 70496 | <1% | 95 | $574.21 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,706 | $572.62 |
| 81001 | <1% | 17,643 | $552.54 | |
| 97163 | <1% | 170 | $539.95 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,904 | $535.38 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 65 | $494.12 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 909 | $459.63 |
| 72128 | <1% | 34 | $451.93 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,591 | $402.50 |
| 87081 | <1% | 1,393 | $335.04 | |
| 74018 | <1% | 429 | $327.55 | |
| 84703 | <1% | 5,513 | $326.96 | |
| 83735 | <1% | 10,270 | $311.43 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,181 | $278.28 |
| 90715 | <1% | 1,805 | $276.66 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,480 | $271.07 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,710 | $265.07 |
| 83880 | <1% | 3,717 | $240.34 | |
| 93976 | <1% | 230 | $233.42 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,257 | $225.29 |
| 80076 | <1% | 1,951 | $211.72 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 28 | $207.50 |
| 87186 | <1% | 2,640 | $191.37 | |
| 12002 | <1% | 66 | $183.50 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,743 | $177.01 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,579 | $174.97 |
| 87088 | <1% | 6,938 | $164.86 | |
| 86850 | <1% | 1,026 | $155.59 | |
| 81003 | <1% | 3,652 | $152.05 | |
| 83605 | <1% | 4,256 | $151.32 | |
| 87070 | <1% | 300 | $150.94 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,493 | $148.22 |
| 85730 | <1% | 5,598 | $148.13 | |
| 84702 | <1% | 1,494 | $145.94 | |
| 87040 | <1% | 2,745 | $133.45 | |
| A9270 | Non-covered item or service | <1% | 5,325 | $130.35 |
| 73502 | <1% | 330 | $129.74 | |
| J3490 | Unclassified drugs | <1% | 2,141 | $126.43 |
| 85610 | <1% | 7,936 | $126.07 | |
| 85379 | <1% | 2,555 | $120.03 | |
| 82962 | <1% | 6,694 | $115.92 | |
| 87430 | <1% | 1,379 | $103.28 | |
| 76801 | <1% | 821 | $102.73 | |
| 85027 | <1% | 2,193 | $100.05 | |
| 76830 | Ultrasound, transvaginal | <1% | 183 | $97.04 |
| 82550 | <1% | 2,629 | $88.87 | |
| 73110 | <1% | 392 | $86.91 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 946 | $80.17 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,586 | $60.57 |
| 87077 | <1% | 1,831 | $58.68 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,935 | $57.44 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,261 | $48.23 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 947 | $45.97 |
| 97116 | <1% | 379 | $41.87 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,101 | $39.37 |
| J1815 | Injection, insulin, per 5 units | <1% | 254 | $36.66 |
| 87420 | <1% | 432 | $34.35 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,832 | $32.51 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 37 | $29.79 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 224 | $29.09 |
| 84100 | <1% | 2,297 | $28.90 | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,583 | $28.06 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,163 | $23.61 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,300 | $22.82 |
| 86901 | <1% | 1,932 | $22.55 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,781 | $19.87 |
| 86900 | <1% | 1,932 | $18.07 | |
| 99001 | <1% | 2,506 | $16.92 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,467 | $11.08 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 566 | $9.93 |
| 84439 | <1% | 104 | $9.32 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 691 | $7.28 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,557 | $6.50 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 744 | $6.32 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 3,145 | $3.92 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,137 | $3.70 |
| 87205 | <1% | 327 | $3.42 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,004 | $3.07 |
| 88304 | 0% | 211 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 17 | $0.00 |
| 96368 | 0% | 162 | $0.00 | |
| A9150 | Non-prescription drugs | 0% | 144 | $0.00 |
| 87147 | 0% | 251 | $0.00 | |
| 73560 | 0% | 52 | $0.00 | |
| 86140 | 0% | 274 | $0.00 | |
| 82270 | 0% | 12 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 296 | $0.00 |
| 85018 | 0% | 332 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 621 | $0.00 |
| 85651 | 0% | 120 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 94 | $0.00 |
| 73564 | 0% | 33 | $0.00 | |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | 0% | 79 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 16 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 42 | $0.00 |
| 71101 | 0% | 39 | $0.00 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 31 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 34 | $0.00 |
| 73620 | 0% | 40 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 33 | $0.00 |
| 73090 | 0% | 15 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 13 | $0.00 |
| 82728 | 0% | 15 | $0.00 | |
| 90686 | 0% | 14 | $0.00 | |
| 83615 | 0% | 14 | $0.00 | |
| 74022 | 0% | 12 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 28 | $0.00 |
| C1769 | Guide wire | 0% | 14 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 1,339 | $0.00 |
| 73590 | 0% | 128 | $0.00 | |
| 84145 | 0% | 32 | $0.00 | |
| 73140 | 0% | 26 | $0.00 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | 0% | 66 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 27 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 508 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 176 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 362 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 96 | $0.00 |
| 29515 | 0% | 24 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 233 | $0.00 |
| 72100 | 0% | 166 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 205 | $0.00 |
| 96367 | 0% | 154 | $0.00 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 0% | 291 | $0.00 |
| 87210 | 0% | 85 | $0.00 | |
| 82805 | 0% | 54 | $0.00 | |
| 73080 | 0% | 55 | $0.00 | |
| 12011 | 0% | 13 | $0.00 | |
| 51702 | 0% | 46 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 38 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 27 | $0.00 |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBLACKWELL, KELSIE (CFO)
| Provider | Location | Paid |
|---|---|---|
| VHS of Phoenix INC | Phoenix, AZ | $52.47M |
| VHS of Phoenix INC | Mesa, AZ | $1000K |
| VHS Acquisition Subsidiary Number 1 INC | Cave Creek, AZ | $618K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.